Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Sipuleucel-T Helps ADT Boost Prostate Cancer Immunity

August 28th 2014

Sipuleucel-T (Provenge) is effective when given either before or after androgen deprivation therapy (ADT) in men with biochemically recurrent prostate cancer (BRPC) who face a high risk of developing metastases, a study has found.

Pembrolizumab Combination Study Planned in Prostate Cancer

August 27th 2014

Advaxis and Merck have entered into a clinical trial collaboration agreement to evaluate the combination of two novel immunotherapies for the treatment of patients with metastatic castration-resistant prostate cancer.

Urologist Perspectives Affect Treatments for Prostate Cancer

August 26th 2014

A physician's perspective, and the therapies he most often prescribes, can have a big influence on whether his patients with low-risk prostate cancer are treated or put on active surveillance, a study has found.

Prostate Cancer in Younger Men a Separate Phenotype

August 22nd 2014

Prostate cancer that emerges when a man is 55 years of age or younger is a distinct phenotype of the disease, and should be treated and researched accordingly,

In 2 Cancers, Robotic Versus Open Surgery is Explored

August 20th 2014

In recent studies, robotic-assisted surgery was explored as a treatment for both prostate and kidney cancers.

In Prostate Cancer, Depression Means Less Treatment, Worse Outcomes

August 19th 2014

Men diagnosed with prostate cancer after being diagnosed with depression were less likely to undergo definitive treatment for their cancer and had worse overall survival.

The Cognitive Error Paradigm

August 15th 2014

As fellows in oncology, we are constantly required to assimilate data, interpret diagnostic tests, decide on appropriate treatment regimens, and employ compassionate care in an increasingly truncated allotment of time.

Free Testosterone May Dictate Necessary Treatment in Prostate Cancer

August 8th 2014

Research from Chile suggests that low levels of free testosterone indicate that an apparently low-risk case of prostate cancer will require treatment.

Dr. Freedland on the Association Between Carbohydrates and Prostate Cancer Risk

August 6th 2014

Stephen J. Freedland, MD, associate professor, Duke University, discusses an analysis presented at the 2014 AUA Annual Meeting that looked at carbohydrate intake, glycemic index, and prostate cancer risk.

AUA Adds Radium-223 to Treatment Guidelines for mCRPC

August 6th 2014

The American Urological Association (AUA) has added recommendations for the use of radium-223 to its treatment guidelines for castration-resistant prostate cancer

Dr. Brawer on Predicting Radical Prostatectomy Outcomes

July 22nd 2014

Michael Brawer, MD, vice president, Medical Affairs, Myriad Genetics, discusses a study that looked at predicting radical prostatectomy outcomes.

Dr. Petrylak on PSMA ADC for Patients with mCRPC

July 21st 2014

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses the results of a phase II trial that examined prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC) patients.

Giants of Cancer Care Heralded: Ceremony Honors 2nd Annual Giants Class

July 16th 2014

The 2nd Annual Giants of Cancer Careâ„¢ Awards were presented at a ceremony held on May 30 in Chicago. The event recognized 16 oncology heroes whose groundbreaking contributions to the field have improved the lives of patients with cancer.

Advanced Prostate Cancer Clinics Keep Urologists, Patients Together

July 10th 2014

When a patient develops advanced prostate cancer, that doesn't mean his urologist needs to bid him farewell.

Radium-223, Abiraterone to be Studied in Combination

July 9th 2014

Two recently approved drugs for the treatment of advanced prostate cancer-radium-223 (Xofigo) and abiraterone acetate (Zytiga)-will be studied in combination in a phase III clinical trial.

Thomas A. Neville, PhD, Discusses PSA Growth Rate

July 8th 2014

Thomas A. Neville, PhD, CEO of Soar Biodynamics in Incline Village, Nevada, discusses PSA growth rate.

Dr. Moul Discusses the Long-Term Tolerability and Efficacy of Degarelix

July 3rd 2014

Judd W. Moul, MD, director, Duke Prostate Center, James H. Semans, MD, Professor of Surgery, Duke University Medical Center, discusses the 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix

Is Death From Prostate Cancer the Right Clinical Endpoint to Guide Screening and Treatment Choices?

July 3rd 2014

There are few controversies in oncology as divisive as the value of prostate-specific antigen (PSA) screening and subsequent treatment for prostate cancer.

Dr. Einhorn on Improving the Cure Rate and the Burden of Cure in Prostate Cancer

July 1st 2014

Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.

With ADT in PC, Managing Side Effects Increasingly Important

July 1st 2014

Androgen-deprivation therapy (ADT) is a mainstay of treatment for prostate cancer in a number of settings, so managing its side effects is becoming increasingly important for urologists in collaboration with oncologists and primary-care physicians.